Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 6 | 2021 | 105 | 1.280 |
Why?
|
| Body Weight | 1 | 2024 | 971 | 0.640 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2007 | 104 | 0.570 |
Why?
|
| Cholangiocarcinoma | 3 | 2007 | 124 | 0.530 |
Why?
|
| Bile Duct Neoplasms | 3 | 2007 | 125 | 0.530 |
Why?
|
| Hepatectomy | 3 | 2008 | 119 | 0.530 |
Why?
|
| Postoperative Complications | 8 | 2025 | 3073 | 0.520 |
Why?
|
| Pancreatectomy | 4 | 2025 | 144 | 0.510 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2016 | 9 | 0.490 |
Why?
|
| Pylorus | 1 | 2016 | 20 | 0.490 |
Why?
|
| Drainage | 5 | 2019 | 252 | 0.480 |
Why?
|
| Gastric Emptying | 1 | 2016 | 77 | 0.470 |
Why?
|
| Jejunum | 1 | 2016 | 122 | 0.460 |
Why?
|
| Liver | 5 | 2011 | 1765 | 0.450 |
Why?
|
| Liver Neoplasms | 7 | 2010 | 1351 | 0.450 |
Why?
|
| Gastroparesis | 1 | 2016 | 68 | 0.450 |
Why?
|
| Liver Transplantation | 9 | 2011 | 1105 | 0.440 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2010 | 968 | 0.430 |
Why?
|
| Stomach | 1 | 2016 | 267 | 0.410 |
Why?
|
| Pancreatic Fistula | 2 | 2014 | 28 | 0.400 |
Why?
|
| Pancreaticojejunostomy | 1 | 2012 | 6 | 0.380 |
Why?
|
| Obesity | 1 | 2024 | 2338 | 0.380 |
Why?
|
| Cyanoacrylates | 1 | 2012 | 12 | 0.380 |
Why?
|
| Tissue Adhesives | 1 | 2012 | 37 | 0.370 |
Why?
|
| Cell Transplantation | 1 | 2011 | 35 | 0.360 |
Why?
|
| Hepatic Stellate Cells | 1 | 2011 | 28 | 0.360 |
Why?
|
| Ampulla of Vater | 1 | 2010 | 15 | 0.340 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2010 | 10 | 0.340 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 30 | 0.340 |
Why?
|
| Yttrium Radioisotopes | 5 | 2009 | 27 | 0.330 |
Why?
|
| Hepatocytes | 1 | 2011 | 231 | 0.320 |
Why?
|
| Tissue Engineering | 1 | 2011 | 166 | 0.310 |
Why?
|
| Tumor Burden | 1 | 2010 | 231 | 0.300 |
Why?
|
| Pilot Projects | 4 | 2016 | 1399 | 0.290 |
Why?
|
| Middle Aged | 20 | 2025 | 27807 | 0.280 |
Why?
|
| Jehovah's Witnesses | 1 | 2007 | 17 | 0.270 |
Why?
|
| Cyclosporine | 4 | 2002 | 127 | 0.260 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2007 | 85 | 0.260 |
Why?
|
| Patient Selection | 1 | 2010 | 711 | 0.240 |
Why?
|
| Perfusion | 1 | 2007 | 207 | 0.240 |
Why?
|
| Obesity, Morbid | 1 | 2008 | 198 | 0.240 |
Why?
|
| Quality of Life | 3 | 2025 | 2029 | 0.230 |
Why?
|
| Pancreatitis, Chronic | 1 | 2025 | 70 | 0.220 |
Why?
|
| Bahrain | 1 | 2024 | 3 | 0.220 |
Why?
|
| Postoperative Care | 2 | 2019 | 306 | 0.220 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1560 | 0.220 |
Why?
|
| Immunosuppressive Agents | 4 | 2002 | 654 | 0.200 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 303 | 0.190 |
Why?
|
| Female | 24 | 2025 | 68592 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 713 | 0.180 |
Why?
|
| Carcinosarcoma | 1 | 2021 | 11 | 0.170 |
Why?
|
| B7 Antigens | 1 | 2020 | 14 | 0.170 |
Why?
|
| Humans | 32 | 2025 | 127268 | 0.170 |
Why?
|
| Adult | 11 | 2025 | 30530 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2019 | 6239 | 0.160 |
Why?
|
| Aged | 12 | 2025 | 20427 | 0.160 |
Why?
|
| Treatment Outcome | 11 | 2019 | 12570 | 0.150 |
Why?
|
| Male | 19 | 2025 | 62778 | 0.150 |
Why?
|
| Neoplasm Staging | 4 | 2010 | 1285 | 0.150 |
Why?
|
| Microspheres | 3 | 2009 | 68 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2024 | 1659 | 0.140 |
Why?
|
| Prevalence | 1 | 2024 | 2613 | 0.130 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 3932 | 0.130 |
Why?
|
| Radiopharmaceuticals | 2 | 2009 | 161 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 110 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 165 | 0.120 |
Why?
|
| Metabolic Diseases | 2 | 2017 | 132 | 0.120 |
Why?
|
| Nutritional Support | 1 | 2017 | 67 | 0.120 |
Why?
|
| Pyloric Antrum | 1 | 2016 | 63 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 754 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 3681 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 630 | 0.110 |
Why?
|
| Glucose | 2 | 2011 | 839 | 0.110 |
Why?
|
| Angiography | 2 | 2005 | 192 | 0.110 |
Why?
|
| Young Adult | 2 | 2024 | 9694 | 0.110 |
Why?
|
| Length of Stay | 4 | 2014 | 1377 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 6694 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 5142 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 753 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 873 | 0.090 |
Why?
|
| Administration, Topical | 1 | 2012 | 131 | 0.090 |
Why?
|
| Lactates | 1 | 2011 | 78 | 0.090 |
Why?
|
| Jejunostomy | 2 | 2009 | 21 | 0.090 |
Why?
|
| Coculture Techniques | 1 | 2011 | 230 | 0.090 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 253 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2020 | 4975 | 0.080 |
Why?
|
| Survival Rate | 4 | 2010 | 2105 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 1357 | 0.080 |
Why?
|
| Resource Allocation | 1 | 2010 | 52 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2010 | 325 | 0.080 |
Why?
|
| Risk Factors | 3 | 2019 | 10603 | 0.080 |
Why?
|
| Cell Survival | 1 | 2011 | 841 | 0.080 |
Why?
|
| Reoperation | 1 | 2012 | 821 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 787 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1386 | 0.070 |
Why?
|
| Hepatic Artery | 2 | 2005 | 46 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2012 | 413 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2009 | 135 | 0.070 |
Why?
|
| Oxygen | 1 | 2011 | 541 | 0.070 |
Why?
|
| Radiography, Interventional | 2 | 2005 | 84 | 0.070 |
Why?
|
| Swine | 1 | 2011 | 1173 | 0.070 |
Why?
|
| Prognosis | 2 | 2023 | 4791 | 0.070 |
Why?
|
| Hemodilution | 1 | 2007 | 14 | 0.070 |
Why?
|
| Procaine | 1 | 2007 | 12 | 0.070 |
Why?
|
| Potassium Chloride | 1 | 2007 | 45 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 14 | 0.070 |
Why?
|
| Adolescent | 4 | 2024 | 20141 | 0.070 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 973 | 0.070 |
Why?
|
| Melphalan | 1 | 2007 | 43 | 0.070 |
Why?
|
| Logistic Models | 1 | 2012 | 1788 | 0.070 |
Why?
|
| Mannitol | 1 | 2007 | 40 | 0.070 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2007 | 23 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 1053 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2018 | 17051 | 0.060 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 99 | 0.060 |
Why?
|
| Tissue and Organ Procurement | 1 | 2010 | 248 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2007 | 169 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 1368 | 0.060 |
Why?
|
| Gastritis | 1 | 2009 | 371 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 2855 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2011 | 2897 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2007 | 286 | 0.060 |
Why?
|
| Hypothermia, Induced | 1 | 2007 | 164 | 0.060 |
Why?
|
| Cisplatin | 1 | 2007 | 269 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2011 | 2397 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2009 | 2047 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 773 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 1235 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 1239 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2005 | 221 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 1205 | 0.050 |
Why?
|
| Liver Function Tests | 1 | 2002 | 97 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 288 | 0.050 |
Why?
|
| Organ Preservation | 1 | 2003 | 62 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2002 | 302 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 1539 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2002 | 1147 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2002 | 766 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2023 | 900 | 0.040 |
Why?
|
| Time Factors | 2 | 2019 | 6160 | 0.040 |
Why?
|
| Enterocytes | 1 | 2021 | 65 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2002 | 274 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 247 | 0.040 |
Why?
|
| Amylases | 1 | 2019 | 21 | 0.040 |
Why?
|
| Tissue Donors | 2 | 2000 | 506 | 0.040 |
Why?
|
| Incidence | 2 | 2019 | 3260 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 154 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 398 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 2 | 2009 | 16 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 378 | 0.030 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 14 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1598 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2000 | 476 | 0.030 |
Why?
|
| Device Removal | 1 | 2018 | 220 | 0.030 |
Why?
|
| Pancreas | 1 | 2017 | 215 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2020 | 742 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2005 | 201 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2017 | 299 | 0.030 |
Why?
|
| Malnutrition | 1 | 2017 | 150 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 565 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 989 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 16 | 0.030 |
Why?
|
| Liver Diseases | 1 | 1998 | 381 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1854 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2008 | 1498 | 0.020 |
Why?
|
| Biomarkers | 2 | 2017 | 3234 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 1194 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2009 | 3716 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1303 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 33187 | 0.020 |
Why?
|
| Gastroscopy | 1 | 2009 | 96 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1759 | 0.020 |
Why?
|
| Emulsions | 2 | 1998 | 69 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2009 | 69 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2008 | 19 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2008 | 36 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2009 | 279 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 2995 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2009 | 380 | 0.010 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2005 | 24 | 0.010 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2005 | 45 | 0.010 |
Why?
|
| United States | 1 | 2020 | 11379 | 0.010 |
Why?
|
| Bilirubin | 1 | 2003 | 124 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 423 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 2119 | 0.010 |
Why?
|
| Color | 1 | 2000 | 32 | 0.010 |
Why?
|
| Audiovisual Aids | 1 | 2000 | 23 | 0.010 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2000 | 39 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 241 | 0.010 |
Why?
|
| Living Donors | 1 | 1998 | 115 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1998 | 177 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 537 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1998 | 685 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 534 | 0.010 |
Why?
|
| Child | 3 | 1998 | 25274 | 0.010 |
Why?
|
| Infant | 2 | 1998 | 12802 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1998 | 14443 | 0.010 |
Why?
|